- Home
- OTLY vs PGEN Comparison
OTLY vs PGEN Comparison
Compare OTLY & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLY
- PGEN
- Stock Information
- Founded
- OTLY 1994
- PGEN 1998
- Country
- OTLY Sweden
- PGEN United States
- Employees
- OTLY N/A
- PGEN N/A
- Industry
- OTLY Packaged Foods
- PGEN Biotechnology: Pharmaceutical Preparations
- Sector
- OTLY Consumer Staples
- PGEN Health Care
- Exchange
- OTLY Nasdaq
- PGEN Nasdaq
- Market Cap
- OTLY 395.7M
- PGEN 371.9M
- IPO Year
- OTLY 2021
- PGEN N/A
- Fundamental
- Price
- OTLY $0.69
- PGEN $1.11
- Analyst Decision
- OTLY Buy
- PGEN Buy
- Analyst Count
- OTLY 3
- PGEN 5
- Target Price
- OTLY $1.27
- PGEN $6.33
- AVG Volume (30 Days)
- OTLY 2.9M
- PGEN 2.4M
- Earning Date
- OTLY 02-12-2025
- PGEN 11-14-2024
- Dividend Yield
- OTLY N/A
- PGEN N/A
- EPS Growth
- OTLY N/A
- PGEN N/A
- EPS
- OTLY N/A
- PGEN N/A
- Revenue
- OTLY $813,471,000.00
- PGEN $3,963,000.00
- Revenue This Year
- OTLY $7.92
- PGEN N/A
- Revenue Next Year
- OTLY $6.69
- PGEN $402.12
- P/E Ratio
- OTLY N/A
- PGEN N/A
- Revenue Growth
- OTLY 5.06
- PGEN N/A
- 52 Week Low
- OTLY $0.60
- PGEN $0.65
- 52 Week High
- OTLY $1.40
- PGEN $1.93
- Technical
- Relative Strength Index (RSI)
- OTLY 53.12
- PGEN 58.19
- Support Level
- OTLY $0.65
- PGEN $1.05
- Resistance Level
- OTLY $0.69
- PGEN $1.46
- Average True Range (ATR)
- OTLY 0.05
- PGEN 0.15
- MACD
- OTLY 0.00
- PGEN 0.00
- Stochastic Oscillator
- OTLY 49.39
- PGEN 54.55
About OTLY Oatly Group AB
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, and Icecreams, among others. It caters to Sweden, Germany, the United Kingdom, Netherlands, North America, Finland, and Other markets. The company generates revenue from the EMEA, Americas, and Asia regions, with the majority of revenue generated from the EMEA region.
About PGEN Precigen Inc.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.